Publications by authors named "Debora D Papaiz"
Article Synopsis
- The study investigates the epigenetic changes in melanoma progression using a four-stage cell line model, examining how CpG methylation varies across different stages: from non-tumorigenic melanocytes to metastatic melanoma cells.
- Researchers identified specific gene promoters that are hypo- and hypermethylated, which characterize distinct malignancy and metastasis signatures, totaling 540 hypo- and 37 hypermethylated promoters for malignancy, and 646 hypo- and 520 hypermethylated promoters for metastasis.
- The findings suggest that specific CpGs could serve as potential markers for predicting poor survival in melanoma patients, as they showed a correlation between DNA methylation and transcriptional levels in key genes linked to melanoma prognosis.
Article Synopsis
- Epigenetic changes, such as DNA methylation, play a crucial role in the development and progression of melanoma, alongside genetic mutations.* -
- The study aimed to discover how methylation of promoter and gene body regions affects gene expression, linking these changes to various stages of melanoma progression using a linear mouse model.* -
- Key genes related to tumor growth (Adcy3) and metastasis (Inpp4b) were identified, and the findings showed a correlation between the mouse model's results and clinical data from melanoma patient cohorts, suggesting possible prognostic markers.*
Article Synopsis
- Despite improvements in treatment, melanoma still often leads to poor patient outcomes, and there is a lack of effective biological models to study its progression.
- Researchers analyzed the gene expression profiles of various melanoma cell lines representing different stages of the disease, finding distinct gene expression patterns linked to cell differentiation and mesenchymal transitions.
- The study identified several genes that could serve as prognostic markers for melanoma progression, enhancing our understanding of the disease and suggesting potential new drug targets.
The Autism Spectrum Disorder (ASD) consists of a prevalent and heterogeneous group of neurodevelopmental diseases representing a severe burden to affected individuals and their caretakers. Despite substantial improvement towards understanding of ASD etiology and pathogenesis, as well as increased social awareness and more intensive research, no effective drugs have been successfully developed to resolve the main and most cumbersome ASD symptoms. Hence, finding better treatments, which may act as "disease-modifying" agents, and novel biomarkers for earlier ASD diagnosis and disease stage determination are needed.
View Article and Find Full Text PDF